Hardware-native
Reads as the chip itself — the microfluidic device, the wells, the channels. Native to chip-makers and instrument vendors.
A category-grade .com positioned for the next generation of organ-on-chip platforms, microfluidic drug-testing systems, and the preclinical infrastructure replacing animal models.
The FDA Modernization Act 2.0 cleared the path for non-animal preclinical testing. The companies building that replacement layer need a name that signals exactly what they do.
OrganicsOnChip is the rare exact-match .com that reads native to every layer of the organ-on-chip stack — hardware, biology, software, and services.
Reads as the chip itself — the microfluidic device, the wells, the channels. Native to chip-makers and instrument vendors.
"Organics" carries the biological tissue meaning. Reads as the cellular models, the mini-organs, the live biology on the chip.
Equally credible as the analytics platform that processes chip output — cell viability data, dose-response curves, pharmacokinetics.
Works as the contract research operator running chips on behalf of pharma sponsors — "OrganicsOnChip ran our hepatotoxicity panel."
The acquisition standard for institutional credibility. A signal to FDA reviewers, pharma partners, and Series A investors that you're a real operator.
"Organ-on-chip" is the searched term. Owning the apex variant captures category navigation traffic from day one.
Broad enough to anchor a category, narrow enough to stay credible at any layer of the preclinical stack.
Design and produce microfluidic chips for liver, heart, lung, gut, and BBB models. Sell devices to pharma R&D and academic labs.
Run hepatotoxicity, cardiotoxicity, and ADME panels on behalf of pharma sponsors. Replace mouse studies with FDA-aligned chip data.
Cloud platform that ingests chip-derived data, runs dose-response modeling, and outputs FDA-ready reports.
The "Etsy for organs-on-chip" — a marketplace connecting pharma buyers with specialized chip vendors and validated tissue models.
A multi-sponsor research network for cross-validating chip protocols against in-vivo and clinical data.
The teaching, training, and certification body for the next decade of organ-on-chip practitioners and FDA reviewers.
A category-grade .com positioned for the post-animal-model era of preclinical research. Currently held by a private owner. Inquiries reviewed within one week. Serious offers only.
BROCKLEY@PM.ME · NO BROKERS WITHOUT REPRESENTATION